特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
599839

世界のインスリンバイオシミラー:世界市場見通し

Insulin Biosimilars - Global Market Outlook (2017-2023)

出版日: | 発行: Stratistics Market Research Consulting | ページ情報: 英文 167 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.83円
世界のインスリンバイオシミラー:世界市場見通し
出版日: 2017年11月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 167 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界のインスリンバイオシミラー市場について調査し、市場の概要とバイオシミラー別、適応別、および地域別の動向、市場に参入する企業のプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 序論

第3章 市場動向分析

  • イントロダクション
  • 促進因子
  • 阻害因子
  • 機会
  • 脅威
  • 新興市場
  • 将来の市場シナリオ

第4章 ファイブフォース分析

第5章 バイオシミラー別別市場

  • イントロダクション
  • 即時作用バイオシミラー
  • 長期作用バイオシミラー
  • プレミクスバイオシミラー

第6章 適応別市場

  • イントロダクション
  • 1型糖尿病
  • 2型糖尿病

第7章 地域別市場

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋地域
  • 南米
  • 中東・アフリカ

第8章 主な動向

  • 合意・提携・連携・合弁
  • 合併・買収
  • 新製品上市
  • 拡充
  • その他の主な戦略

第9章 企業プロファイリング

  • Wockhardt Limited
  • Ypsomed AG
  • Pfizer Inc.
  • Mylan N.V.
  • Boehringer Ingelheim GmbH
  • NOVO Nordisk A/S
  • Sanofi S.A.
  • Merck & Co.
  • Biocon Limited
  • Eli Lilly & Co.
目次

Stratistics MRC, are pleased to announce the latest publication of Global Insulin Biosimilars market. Growing pervasiveness of type 1 diabetes and ongoing approvals by the government authorities are nurturing the market growth. Some of the factors such as growing population exposures, technological developments and favorable medical repayment scenario in developed countries are poised to favour the market growth. However, patent protection rights of insulin and strong vengeance from the key manufacturers are some of the restraints limiting the market.

Expansion of clinically verified insulin biosimilar will cover the road for new entrants. The approaching patent expiration of insulin drugs will unlock new opportunities for the development of biosimilars and manufacturing companies. As cost is high due to strict observance requirements, prices of biosimilar drugs are anticipated to decrease as compared to branded drugs.

North America led the insulin biosimilars market due to rising demand for insulin in the region. Europe is anticipated to account for second largest share and Asia Pacific is expected to grow at a fastest rate during the forecast period. APAC players are competing on the basis of price and have pool of patients affected by diabetes, thus fueling the market growth.

Some of the key players in this market are Wockhardt Limited, Ypsomed AG, Pfizer Inc., Mylan N.V., Boehringer Ingelheim GmbH, NOVO Nordisk A/S, Sanofi S.A., Merck & Co., Biocon Limited and Eli Lilly & Co.

Biosimilars Types Covered:

  • Rapid-Acting Biosimilars
  • Long-Acting Biosimilars
  • Premixed Biosimilars

Disease Indications Covered:

  • Type I Diabetes
  • Type II Diabetes

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country level segments
  • Market share analysis of the top industry players
  • Strategic recommendations for the new entrants
  • Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Futuristic Market Scenario

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Insulin Biosimilars Market, By Biosimilars Type

  • 5.1 Introduction
  • 5.2 Rapid-Acting Biosimilars
  • 5.3 Long-Acting Biosimilars
  • 5.4 Premixed Biosimilars

6 Global Insulin Biosimilars Market, By Disease Indication

  • 6.1 Introduction
  • 6.2 Type I Diabetes
  • 6.3 Type II Diabetes

7 Global Insulin Biosimilars Market, By Geography

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 US
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 Italy
    • 7.3.4 France
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 New Zealand
    • 7.4.6 South Korea
    • 7.4.7 Rest of Asia Pacific
  • 7.5 South America
    • 7.5.1 Argentina
    • 7.5.2 Brazil
    • 7.5.3 Chile
    • 7.5.4 Rest of South America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 UAE
    • 7.6.3 Qatar
    • 7.6.4 South Africa
    • 7.6.5 Rest of Middle East & Africa

8 Key Developments

  • 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 8.2 Acquisitions & Mergers
  • 8.3 New Product Launch
  • 8.4 Expansions
  • 8.5 Other Key Strategies

9 Company Profiling

  • 9.1 Wockhardt Limited
  • 9.2 Ypsomed AG
  • 9.3 Pfizer Inc.
  • 9.4 Mylan N.V.
  • 9.5 Boehringer Ingelheim GmbH
  • 9.6 NOVO Nordisk A/S
  • 9.7 Sanofi S.A.
  • 9.8 Merck & Co.
  • 9.9 Biocon Limited
  • 9.10 Eli Lilly & Co.

List Of Tables

  • Table 1 Global Insulin Biosimilars Market Outlook, By Region (2014-2023) ($MN)
  • Table 2 Global Insulin Biosimilars Market Outlook, By Biosimilars Type (2014-2023) ($MN)
  • Table 3 Global Insulin Biosimilars Market Outlook, By Rapid-Acting Biosimilars (2014-2023) ($MN)
  • Table 4 Global Insulin Biosimilars Market Outlook, By Long-Acting Biosimilars (2014-2023) ($MN)
  • Table 5 Global Insulin Biosimilars Market Outlook, By Premixed Biosimilars (2014-2023) ($MN)
  • Table 6 Global Insulin Biosimilars Market Outlook, By Disease Indication (2014-2023) ($MN)
  • Table 7 Global Insulin Biosimilars Market Outlook, By Type I Diabetes (2014-2023) ($MN)
  • Table 8 Global Insulin Biosimilars Market Outlook, By Type II Diabetes (2014-2023) ($MN)
  • Table 9 North America Insulin Biosimilars Market Outlook, By Country (2014-2023) ($MN)
  • Table 10 North America Insulin Biosimilars Market Outlook, By Biosimilars Type (2014-2023) ($MN)
  • Table 11 North America Insulin Biosimilars Market Outlook, By Rapid-Acting Biosimilars (2014-2023) ($MN)
  • Table 12 North America Insulin Biosimilars Market Outlook, By Long-Acting Biosimilars (2014-2023) ($MN)
  • Table 13 North America Insulin Biosimilars Market Outlook, By Premixed Biosimilars (2014-2023) ($MN)
  • Table 14 North America Insulin Biosimilars Market Outlook, By Disease Indication (2014-2023) ($MN)
  • Table 15 North America Insulin Biosimilars Market Outlook, By Type I Diabetes (2014-2023) ($MN)
  • Table 16 North America Insulin Biosimilars Market Outlook, By Type II Diabetes (2014-2023) ($MN)
  • Table 17 Europe Insulin Biosimilars Market Outlook, By Country (2014-2023) ($MN)
  • Table 18 Europe Insulin Biosimilars Market Outlook, By Biosimilars Type (2014-2023) ($MN)
  • Table 19 Europe Insulin Biosimilars Market Outlook, By Rapid-Acting Biosimilars (2014-2023) ($MN)
  • Table 20 Europe Insulin Biosimilars Market Outlook, By Long-Acting Biosimilars (2014-2023) ($MN)
  • Table 21 Europe Insulin Biosimilars Market Outlook, By Premixed Biosimilars (2014-2023) ($MN)
  • Table 22 Europe Insulin Biosimilars Market Outlook, By Disease Indication (2014-2023) ($MN)
  • Table 23 Europe Insulin Biosimilars Market Outlook, By Type I Diabetes (2014-2023) ($MN)
  • Table 24 Europe Insulin Biosimilars Market Outlook, By Type II Diabetes (2014-2023) ($MN)
  • Table 25 Asia Pacific Insulin Biosimilars Market Outlook, By Country (2014-2023) ($MN)
  • Table 26 Asia Pacific Insulin Biosimilars Market Outlook, By Biosimilars Type (2014-2023) ($MN)
  • Table 27 Asia Pacific Insulin Biosimilars Market Outlook, By Rapid-Acting Biosimilars (2014-2023) ($MN)
  • Table 28 Asia Pacific Insulin Biosimilars Market Outlook, By Long-Acting Biosimilars (2014-2023) ($MN)
  • Table 29 Asia Pacific Insulin Biosimilars Market Outlook, By Premixed Biosimilars (2014-2023) ($MN)
  • Table 30 Asia Pacific Insulin Biosimilars Market Outlook, By Disease Indication (2014-2023) ($MN)
  • Table 31 Asia Pacific Insulin Biosimilars Market Outlook, By Type I Diabetes (2014-2023) ($MN)
  • Table 32 Asia Pacific Insulin Biosimilars Market Outlook, By Type II Diabetes (2014-2023) ($MN)
  • Table 33 South America Insulin Biosimilars Market Outlook, By Country (2014-2023) ($MN)
  • Table 34 South America Insulin Biosimilars Market Outlook, By Biosimilars Type (2014-2023) ($MN)
  • Table 35 South America Insulin Biosimilars Market Outlook, By Rapid-Acting Biosimilars (2014-2023) ($MN)
  • Table 36 South America Insulin Biosimilars Market Outlook, By Long-Acting Biosimilars (2014-2023) ($MN)
  • Table 37 South America Insulin Biosimilars Market Outlook, By Premixed Biosimilars (2014-2023) ($MN)
  • Table 38 South America Insulin Biosimilars Market Outlook, By Disease Indication (2014-2023) ($MN)
  • Table 39 South America Insulin Biosimilars Market Outlook, By Type I Diabetes (2014-2023) ($MN)
  • Table 40 South America Insulin Biosimilars Market Outlook, By Type II Diabetes (2014-2023) ($MN)
  • Table 41 Middle East & Africa Insulin Biosimilars Market Outlook, By Country (2014-2023) ($MN)
  • Table 42 Middle East & Africa Insulin Biosimilars Market Outlook, By Biosimilars Type (2014-2023) ($MN)
  • Table 43 Middle East & Africa Insulin Biosimilars Market Outlook, By Rapid-Acting Biosimilars (2014-2023) ($MN)
  • Table 44 Middle East & Africa Insulin Biosimilars Market Outlook, By Long-Acting Biosimilars (2014-2023) ($MN)
  • Table 45 Middle East & Africa Insulin Biosimilars Market Outlook, By Premixed Biosimilars (2014-2023) ($MN)
  • Table 46 Middle East & Africa Insulin Biosimilars Market Outlook, By Disease Indication (2014-2023) ($MN)
  • Table 47 Middle East & Africa Insulin Biosimilars Market Outlook, By Type I Diabetes (2014-2023) ($MN)
  • Table 48 Middle East & Africa Insulin Biosimilars Market Outlook, By Type II Diabetes (2014-2023) ($MN)
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.